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Effectiveness of Drug-Eluting Stents versus Bare-Metal Stents  
in Large Coronary Arteries in Patients with Acute Myocardial 
Infarction
This study compared clinical outcomes of drug-eluting stents (DES) versus bare-metal 
stents (BMS) in large coronary arteries in patients with acute myocardial infarction (MI). A 
total of 985 patients who underwent single-vessel percutaneous coronary intervention (PCI) 
in large coronary arteries (≥ 3.5 mm) in lesions < 25 mm were divided into DES group  
(n = 841) and BMS group (n = 144). Clinical outcomes during 12 months were compared. 
In-hospital outcome was similar between the groups. At six months, death/MI rate was 
not different. However, DES group had significantly lower rates of target-lesion 
revascularization (TLR) (1.7% vs 5.6%, P = 0.021), target-vessel revascularization (TVR) 
(2.2% vs 5.6%, P = 0.032), and total major adverse cardiac events (MACE) (3.4% vs 
11.9%, P = 0.025). At 12 months, the rates of TLR and TVR remained lower in the DES 
group (2.5% vs 5.9%, P = 0.032 and 5.9% vs 3.1%, P = 0.041), but the rates of death/MI 
and total MACE were not statistically different. The use of DES in large vessels in the 
setting of acute MI is associated with lower need for repeat revascularization compared to 
BMS without compromising the overall safety over the course of one-year follow-up.
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INTRODUCTION
Vessel size is an important risk predictor of clinical and angio-
graphic outcomes in patients undergoing percutaneous coro-
nary intervention (PCI) (1, 2). Small reference diameter has 
been associated with an increased risk of restenosis. In patients 
treated with bare-metal stents (BMS), the impact of vessel size 
is quite obvious because of the limited ability of small size ves-
sels to accommodate to the neointimal proliferation that devel-
ops after stent implantation (2, 3). Drug-eluting stents (DES) 
are effective in reducing restenosis risk compared with BMS in 
patients with coronary artery disease (4-6). The advantages of 
DES over BMS have been shown in different subsets of patients 
and lesions, including that of small coronary vessels (7-9). The 
anti-restenotic efficacy of DES is achieved through inhibition of 
neointimal proliferation, which is shown angiographically by 
the reduced degree of late lumen loss (4). 
  Nevertheless, the superiority of DES over BMS for the treat-Sim DS, et al.  •  Drug-Eluting Stents in Large Coronary Arteries 
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ment of large vessels in patients undergoing high-risk PCI such 
as in the setting of acute myocardial infarction (MI) has yet to 
be defined. We investigated the safety and effectiveness of DES 
versus BMS in large coronary vessels in patients with acute MI 
during 12-month clinical follow-up.
MATERIALS AND METHODS
Patient population
We analyzed data of patients with acute MI who were enrolled 
in the Korea Acute Myocardial Infarction Registry (10, 11) be-
tween November 2005 and December 2007. Patients, entered 
into the registry, were ≥ 18 yr of age at the time of hospital pre-
sentation, had to be admitted for an acute MI as a presumptive 
diagnosis, and have ≥ 1 of the followings: electrocardiographic 
changes consistent with an acute MI, serial increases in serum 
biochemical markers of myocardial necrosis, and/or documen-
tation of coronary artery disease. A total of 1,340 patients with 
acute MI who underwent single-vessel PCI with stents ≥ 3.5 mm 
in diameter were selected and divided into two groups (group 1, 
patients who received DES, n = 1,151; and group 2, patients who 
underwent BMS implantation, n = 189). Given that lesion length 
is also recognized as a predictor of recurrent restenosis, only the 
patients who received stents < 25 mm were included in the anal-
ysis. Three different DES were used: sirolimus-eluting stents 
(Cypher stent, Cordis, Johnson & Johnson, Miami, FL, USA) in 
347 patients, paclitaxel-eluting stents (Taxus stent, Boston Sci-
entific, Natick, MA, USA) in 284 patients, and zotarolimus-elut-
ing stents (Endeavor Sprint stent, Medtronic, Minneapolis, MN, 
USA) in 210 patients. Although BMS were available in a variety 
of large diameters, only those ≤ 4.0 mm were included in the 
present study. 
PCI procedure and medications
Stent implantation was performed with standard interventional 
techniques. Before the procedure, all patients received orally 300 
mg of aspirin and 300 to 600 mg of clopidogrel. During the pro-
cedure, weight-adjusted unfractionated heparin was given at a 
bolus dose of 100 U/kg with additional bolus to maintain acti-
vated clotting time of 250 to 300 sec. The use of other adjunctive 
medications, including glycoprotein IIb/IIIa inhibitors, was left 
to the discretion of the operator. After the procedure, 100 to 300 
mg/day of aspirin was continued indefinitely, and 75 mg/day of 
clopidogrel was maintained for at least 4 weeks in patients with 
BMS and for ≥ 12 months in patients with DES. Baseline clinical 
characteristics, angiographic features, in-hospital mortality, and 
clinical outcomes at follow-up were recorded and entered into 
a dedicated computerized database. 
Study definitions and endpoints
A large coronary vessel was defined as ≥ 3.5 mm in diameter. 
Angiographic success was defined as < 25% diameter residual 
stenosis with Thrombolysis In Myocardial Infarction (TIMI) grade 
3 flow. Clinical success was defined as angiographic success 
without in-hospital complications of death, MI, or coronary ar-
tery bypass graft within 24 hr of the index procedure. Major ad-
verse cardiac events (MACE) included death, MI, and need for 
repeat target-lesion revascularization (TLR) or target-vessel re-
vascularization (TVR). TLR was defined as a repeat intervention 
(surgical or percutaneous) to control luminal stenosis within 
the same vessel segment that was treated at the index procedure. 
TVR was defined as any reintervention driven by lesions locat-
ed in the treated vessel within and beyond the target lesion lim-
its. Non-TVR was defined as any reintervention in vessels other 
than the target vessel. Smoking was defined as any history of 
tobacco smoking. Hypertension was defined as a history of hy-
pertension or antihypertensive medication use, and diabetes 
was defined as a history of diabetes and use of insulin or oral 
hypoglycemic agents on entry into the study. Hypercholesterol-
emia was defined as a diagnosis previously made by a physician 
or by treatment with lipid-lowering medications. Lesion length 
and vessel reference diameter were visually estimated by the 
operators. On-line quantitative coronary analysis was allowed 
if required by the attending physician. Study endpoints were in-
hospital complications including death, MI, bleeding compli-
cations, vascular complications, and the composite end point 
of MACE, including death, MI, and TLR or TVR. Clinical follow-
up with respect to MACE occurred again at 30 days, 6 months 
and 12 months after the baseline procedure.
Statistical analysis
All statistical analyses were performed with SPSS 15.0 for Win-
dows (SPSS Inc.). Continuous variables were presented as mean    
± SD and were compared by Student t test (when the group dis-
tributions were symmetrical and mounded) or Mann-Whitney 
U test (when the group distributions were skewed). The chi-
square test (when all expected cell counts were ≥ 5) or Fisher 
exact test (when any expected cell count was < 5) was used to 
determine the significance of differences in categorical variables. 
Multivariable survival analysis was performed by a Cox-regres-
sion model. All statistical tests were two-tailed, and a P value < 
0.05 was considered statistically significant. To assess selection 
bias not controlled for in our multivariate model, we used a pro-
pensity-adjustment model. We developed propensity scores 
based on the likelihood of receiving DES derived from a logistic 
regression model incorporating 31 variables: age, sex, hyperten-
sion, diabetes, smoking, hyperlipidemia, previous MI, previous 
PCI, previous coronary artery bypass graft surgery, family histo-
ry of MI, treated vessel, American College of Cardiology/Ameri-
can Heart Association lesion type, pre-PCI TIMI flow, stent size, 
stent diameter, ST-elevation MI, anterior MI, cardiogenic shock, 
prior cardiopulmonary resuscitation (CPR), fibrinolysis, ven-Sim DS, et al.  •  Drug-Eluting Stents in Large Coronary Arteries 
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tricular tachycardia/fibrillation, advanced heart block (Mobitz 
type II or III), rescue PCI, intra-aortic balloon pump counter-
pulsation, mechanical ventilation, use of glycoprotein IIb/IIIa 
receptor inhibitor, Killip class III or IV, left ventricular ejection 
fraction, symptom-to-door time, and door-to-balloon time (C-
statistic = 0.768). We incorporated the resultant propensity 
scores into a logistic regression model to negate selection bias 
in examining the effect of propensity for DES use on clinical 
outcome. 
Ethics statement
The study was conducted according to the Declaration of Hel-
sinki. The institutional review board of all participating centers 
approved the study protocol. The approval number was 05-49 
of Chonnam National University Hospital. Written informed 
consent was obtained from all participating patients.
 
RESULTS
The baseline clinical and procedural characteristics are displayed 
in Tables 1, 2. Patients who received BMS were more likely to 
have hypercholesterolemia, Killip class > III, prior CPR, higher 
troponin and triglyceride levels, the right coronary artery as the 
culprit vessel, and more complex lesion types. They were more 
likely to receive stents with larger diameters and shorter lengths 
and to be treated with glycoprotein IIb/IIIa inhibitors during the 
PCI. In contrast, cilostazol was more likely to be used in the DES 
group compared to the BMS group after PCI (37.8% vs 16.7%, P 
< 0.001). BMS group was more likely to be associated with ad-
verse peri-procedural events (Table 3). In-hospital and 30-day 
outcomes are presented in Table 4. Mortality in-hospital and at 
30 days were not different between the groups after controlling 
for confounding variables using propensity scores. At six-month 
Table 1. Baseline clinical characteristics of the study population
Parameters DES (n = 841) BMS (n = 144) P
Age (yr)    57.6 ± 12.5   57.1 ± 12.9 0.631
Male 697 (82.9%) 120 (83.3%) 0.893
Risk factors
   Smoking
   Hypertension
   Diabetes
   Hypercholesterolemia
   Family history
   Previous MI
   Previous PCI
   Previous CAGB
 
591 (70.3%)
313 (37.2%)
154 (18.3%)
70 (8.3%)
63 (7.5%)
14 (1.7%)
26 (3.1%)
1 (0.1%)
 
103 (71.5%)
55 (38.2%)
18 (12.5%)
24 (16.7%)
7 (4.9%)
5 (3.5%)
4 (2.8%)
0
 
0.760
0.823
0.090
0.002
0.256
0.179
0.840
0.679
ST-elevation MI 629 (74.8%) 115 (79.9%) 0.191
Anterior MI 454 (54.0%) 54 (37.5%) < 0.001
Glycoprotein IIb/IIIa inhibitor 103 (12.2%) 28 (19.4%) 0.019
Fibrinolysis 68 (8.1%) 13 (9.0%) 0.704
Rescue PCI 28 (3.3%) 9 (6.3%) 0.089
Killip class ≥ III 45 (5.4%) 14 (9.7%) 0.041
Prior CPR 12 (1.4%) 7 (4.9%) 0.013
Cardiogenic shock 21 (2.5%) 5 (3.5%) 0.570
Left ventricular ejection  
   fraction (%)
52.8 ± 11.3   52.8 ± 11.1 0.973
Glucose (mg/dL) 160.9 ± 63.6 165.9 ± 67.1 0.393
Creatinine (mg/dL)   1.1 ± 0.8   1.1 ± 1.2 0.507
Troponin-I (ng/mL)     53 ± 119     83 ± 142 0.030
Total cholesterol (mg/dL) 184 ± 40 184 ± 52 0.890
Triglyceride (mg/dL) 128 ± 91   158 ± 131 0.011
HDL-cholesterol (mg/dL)   47 ± 22   43 ± 12 0.059
LDL-cholesterol (mg/dL) 119 ± 48 122 ± 45 0.534
hs-CRP (mg/dL)   12 ± 55   15 ± 96 0.566
NT-proBNP (pg/mL )   1,090 ± 3,058   1,231 ± 3,996 0.693
CABG, coronary artery bypass grafting; CPR, cardiopulmonary resuscitation; HDL, 
high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density 
lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCI, percutaneous 
coronary intervention. 
Table 2. Procedural characteristics of the study population
Procedures DES (n = 841) BMS (n = 144) P
Symptom-to-door time (hr) 12.6 ± 46.6 16.9 ± 69.1 0.346
Door-to-balloon time (hr) 21.2 ± 39.7 15.9 ± 28.8 0.056
Treated coronary vessel
   Left anterior descending artery
   Left circumflex artery
   Right coronary artery
 
500 (59.5%)
73 (8.7%)
268 (31.9%)
 
  61 (42.4%)
  17 (11.8%)
  66 (45.8%)
 
< 0.001
0.229
0.001
ACC/AHA lesion type B2/C 554 (65.9%) 111 (77.1%) 0.008
Pre-PCI TIMI 3 260 (30.9%)   37 (25.7%) 0.207
Post-PCI TIMI 3 814 (96.8%) 140 (97.2%) 0.783
Stent diameter (mm) 3.58 ± 0.18 3.71 ± 0.25 < 0.001
Stent length (mm) 20.4 ± 3.29 19.5 ± 3.41 0.001
ACC/AHA, American College of Cardiology/American Heart Association; PCI, percu-
taneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction.
Table 3. Frequeneis of peri-procedural adverse events
Adverse events DES (n = 841) BMS (n = 144) P
CPR during PCI 13 (1.5%)   6 (4.2%) 0.047
Ventricular tachycardia/fibrillation 43 (5.1%) 14 (9.7%) 0.029
Advanced heart block 17 (2.0%)   5 (3.5%) 0.353
Use of intra-aortic balloon pump  45 (5.4%) 14 (9.7%) 0.041
Mechanical ventilation 15 (1.8%)   7 (4.9%) 0.031
Acute kidney injury 0   1 (0.7%) 0.146
Acute stroke   5 (0.6%)   3 (2.1%) 0.098
Major bleeding   1 (0.1%)   1 (0.7%) 0.271
CPR, cardiopulmonary resuscitation; PCI, percutaneous coronary intervention. 
Table 4. In-hospital mortality and 30-day clinical outcomes
Cause of death DES BMS
Unadjusted  
P
Adjusted  
P
In-hospital 
   death
(n = 841)
10 (1.2%)
(n = 144)
6 (4.2%)
 
0.020
 
0.184
30-days death
   MI
   TLR
   TVR
   CABG
   TLR/MACE
   TVR/MACE
(n = 763)
12 (1.6%)
0
  1 (0.1%)
  1 (0.1%)
  1 (0.1%)
12 (1.6%)
12 (1.6%)
(n = 135)
7 (5.2%)
1 (0.7%)
1 (0.7%)
1 (0.7%)
0
9 (6.7%)
9 (6.7%)
 
0.015
0.150
0.278
0.278
0.674
0.002
0.002
 
0.978
0.987
0.933
0.933
0.674
0.846
0.846
MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel 
revascularization; CABG, coronary artery bypass graft surgery; MACE, major adverse 
cardiac events.Sim DS, et al.  •  Drug-Eluting Stents in Large Coronary Arteries 
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follow-up, patients with DES had significantly lower rates of 
TLR (1.7% vs 5.6%, P = 0.021), TVR (2.2% vs 5.6%, P = 0.032), and 
combined MACE, which were mainly driven by lower TLR/TVR 
(Fig. 1, Table 5). At 12 months, the rates of TLR and TVR remained 
significantly lower in patients with DES (2.5% vs 5.9%, P = 0.032 
and 3.1% vs 5.9%, P = 0.041, respectively). However, 12-month 
death/MI rates and composite MACE rates were not significant-
ly different between the groups (Fig. 2, Table 5).
DISCUSSION
The present study showed that the use of DES in large single cul-
prit vessels in patients with acute MI was associated with signif-
icantly lower rates of TLR and TVR without increasing the rates 
of death/MI or composite MACE during a one-year clinical fol-
low-up. This finding demonstrated that the important advan-
tage of a lower restenosis rate with DES relative to BMS existed 
Table 5. Six- and 12-month clinical outcomes
Clinical 
outcomes
DES BMS Unadjusted  
P
Adjusted  
P
6-month n = 650 n = 126
   Death
   MI
   TLR
   TVR
   CABG
   TLR/MACE
   TVR/MACE
14 (2.2%)
0
11 (1.7%)
14 (2.2%)
  1 (0.1%)
22 (3.4%)
25 (3.8%)
7 (5.6%)
1 (0.8%)
7 (5.6%)
7 (5.6%)
0
15 (11.9%)
15 (11.9%)
0.063
0.162
0.017
0.063
0.679
< 0.0005
< 0.0005
0.561
0.926
0.021
0.032
0.982
0.025
0.032
12-month n = 555 n = 118
   Death
   MI
   TLR
   TVR
   CABG
   TLR/MACE
   TVR/MACE
19 (3.4%)
  1 (0.2%)
14 (2.5%)
17 (3.1%)
  1 (0.2%)
34 (6.1%)
37 (6.7%)
7 (5.9%)
1 (0.8%)
7 (5.9%)
7 (5.9%)
0
15 (12.7%)
15 (12.7%)
0.194
0.320
0.074
0.165
0.644
0.018
0.026
0.315
0.277
0.032
0.041
0.979
0.244
0.249
MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel 
revascularization; CABG, coronary artery bypass graft surgery; MACE, major adverse 
cardiac events.
Fig. 1. Target lesion revascularization (TLR)-free survival at 12 months. BMS, bare-
metal stents; DES, drug-eluting stents; PCI, percutaneous coronary intervention.
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Fig. 2. Death/MI-free survival at 12 months. TLR, target lesion revascularization; BMS, 
bare-metal stents; DES, drug-eluting stents; PCI, percutaneous coronary intervention.
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for PCI even in large vessels in the setting of acute MI. 
  DES are now used in preference to BMS in most PCI proce-
dures because they reduce the incidence of restenosis and TVR 
without causing a significant increase in the cumulative rate of 
adverse outcomes. Recently, DES have been increasingly used 
even in patients with acute MI. Most randomized trials, which 
evaluated outcomes at one year or less, suggested that the ben-
efit of DES relative to BMS used for PCI in acute MI patients was 
similar to that in other settings (12-17). Longer-term outcomes 
were also similar between DES to BMS (18-22). The majority of 
the studies found a lower rate of TVR in DES group without in-
creasing death or MI at two to three years’ follow-up. Further-
more, no statistically significant difference was observed in the 
rate of late stent thrombosis between DES and BMS at one to 
three years of follow-up (18, 21, 22). 
  While DES are clearly effective in reducing restenosis rates by 
inhibiting neointimal growth, data from a number of random-
ized trials and registries have shown conflicting results regard-
ing their effectiveness in the treatment of large vessels. Most 
studies showed no differences between BMS and DES in clini-
cal outcomes of PCI in large coronary vessels (5, 6, 8, 23-27). 
BMS in large (≥ 3.0-3.5 mm) vessels appeared as effective as 
DES with lower TLR at six months to three years. In the recent 
BASKET trial (28), the benefit of DES in reducing the rate of isch-
emia-driven TVR persisted up to three years, particularly in pa-
tients with small (< 3 mm) stents (P = 0.03), while being small 
and non-significant in patients with large (≥ 3.0 mm) stents (P = 
0.44). However, the three-year cardiac death/MI rate was signif-
icantly higher in patients with large stents treated with DES due 
to increase in the rate of late stent thrombosis. This new obser-
vation from this trial implies that DES in large vessels are more 
prone to late stent thrombosis and therefore may paradoxically 
portend worse long-term clinical outcome compared to BMS. 
However, given that only 21 percent of the study population had 
acute MI and the study was underpowered to definitely assess Sim DS, et al.  •  Drug-Eluting Stents in Large Coronary Arteries 
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the magnitude of late stent thrombosis, the long-term safety and 
benefit of DES in large vessels in patients with acute MI need to 
be evaluated in a larger prospective setting. In our study, there 
was no overall increase in the rates of the safety endpoints, i.e., 
death or death/MI, in the DES group compared with the BMS 
group, indicating lower incidence of late stent thrombosis in 
DES-treated patients, although stent thrombosis was not in-
cluded as an endpoint in this study. 
  The present study is limited because of its retrospective na-
ture and is therefore subject to the limitations pertinent to this 
type of clinical investigation. This study is not randomized and 
also lacks systematic angiographic follow-up and quantitative 
coronary analysis that seem to increase the rates of TLR and 
TVR. Stent thrombosis was not included as an endpoint in the 
present study. However, death/MI rate was not increased in DES 
compared to BMS over the 12-month period, suggesting that 
the rate of clinically relevant stent thrombosis would have been 
similar between the two groups. Still, longer follow-up is need-
ed to see whether DES in large vessels are indeed associated 
with an increased incidence of late and very late stent throm-
bosis in patients with acute MI, which may then tip the scales in 
favor of BMS in this population. The difference in the sample 
size between the DES and BMS group needs to be taken into 
consideration in interpreting the data. Furthermore, even though 
we used propensity score to adjust for treatment selection bias 
regarding the use of DES during PCI for acute MI, unmeasured 
confounders may have influenced the results. For instance, the 
use of long-term medical therapies that have potential efficacy 
of reducing restenosis might have affected the outcome (29, 30). 
Finally, differences between the institutions involved in this re-
search, although representative of the reality of the country’s 
health system, may to some extent have introduced an unin-
tentional bias.
  In conclusion, our results show that the use of DES in large 
vessels in the setting of acute MI is associated with reduced need 
for repeat revascularization compared to BMS without compro-
mising the overall safety over the course of one-year follow-up.
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Total of 985 patients who underwent single-vessel percutaneous coronary intervention (PCI) in large coronary arteries (≥ 3.5 mm) 
in lesions < 25 mm were divided into DES group (n = 841) and BMS group (n = 144) over the course of one-year follow-up. The 
use of drug-eluting stent for acute myocardial infarction is, without compromising the overall safety, associated with lower need 
for repeated revascularization than bare metal stent. 